Merck (MRK) Wins EU Approval For KEYTRUDA Plus Padcev In Bladder Cancer

Merck (NYSE:MRK) received European Commission approval for KEYTRUDA plus Padcev as a perioperative therapy for resectable muscle-invasive bladder cancer in the EU. The decision covers patients regardless of cisplatin eligibility, widening access to the regimen across a broader bladder cancer population. This is the first European Union authorization for a PD-1 inhibitor used with an antibody-drug conjugate in this disease setting. The European Commission approval of KEYTRUDA plus Padcev in...